Johnson & Johnson Shares Drop on Mixed Earnings Despite Strong Pharmaceutical Performance
Johnson & Johnson (JNJ) shares fell more than 6% after the company reported a mixed third-quarter performance. While revenue rose to $25.4 billion, exceeding expectations by nearly $100 million and adjusted earnings per share beat estimates at $2.59, year-over-year EPS declined due in part to charges from business development deals. The stock's sharp decline was attributed partly to ongoing issues within its medical devices segment, particularly the cardiovascular division and international surgical operations affected by geopolitical factors like Middle East tensions and Chinese procurement policies. Analysts remain optimistic about J&J’s long-term prospects, citing strong growth in pharmaceuticals led by newly launched drug Icotyde. The psoriasis treatment has seen rapid adoption with over 20,000 patients initiated on the therapy since its March FDA approval. Despite short-term challenges, analysts reiterated a buy-equivalent rating and maintained a $275 price target for J&J stock. Jim Cramer highlighted that while the sell-off is partly justified by performance issues in MedTech, it may present an opportunity for long-term investors given J&J’s robust drug pipeline. The company remains at the forefront of healthcare innovation with multiple blockbuster drugs expected to drive future growth.
Tickers: $JNJ
Topics: earnings investment strategy pharmaceuticals stock price movement
Part of the story Johnson & Johnson Shares Decline Premarket Despite Raised Earnings Guidance (3 articles)